

Supplemental Information

Synthesis of spirobarbiturate-pyrrolidinones via a domino aza-Michael/S_N2 cyclization of barbiturate-derived alkenes with *N*-alkoxy α -haloamides

Chuan-Chuan Wang,^{a,b,†} Jing Zhou,^{c,†} Zhi-Wei Ma,^a Xiao-Pei Chen^a
and Ya-Jing Chen^{*,c}

^aFaculty of Science, Henan University of Animal Husbandry and Economy, No. 2 Yingcai Street, Huiji District, Zhengzhou 450044, Henan, PR China

^bCollege of chemistry, Zhengzhou University, 100 Science Avenue, Zhengzhou 450001, Henan, PR China.

^cSchool of Pharmaceutical Sciences; Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China; Co-innovation Center of Henan Province for New Drug R & D and Preclinical Safety, Zhengzhou University, 100 Science Avenue, Zhengzhou 450001, Henan, PR China

[†]C.-C. Wang and J. Zhou contributed equally.

E-mail: chenyj@zzu.edu.cn

Table of Contents

1. General Information.....	S3
2. General Procedure for Synthesis of Barbiturate-Derived Alkenes 1	S3
3. General Procedure for Synthesis of <i>N</i> -Alkoxy α -Haloamides 2	S5
4. References.....	S6
5. Copies of NMR Spectras of Barbiturate-Derived Alkenes 1	S7
6. Copies of NMR Spectras of <i>N</i> -Alkoxy α -Haloamides 2	S20
7. Copies of NMR Spectras of Adducts 3 , 4 and 5	S26

1. General Information

All reactions were performed in oven-dried glassware with magnetic stirring under air atmosphere. Unless otherwise stated, all reagents were purchased from commercial suppliers and used without further purification. All solvents were purified and dried according to standard methods prior to use. Organic solutions were concentrated under reduced pressure on a rotary evaporator or an oil pump. Reactions were monitored through thin layer chromatography (TLC) on silica gel-precoated glass plates. Subsequent to elution, plates were visualized using UV radiation at 254 nm and by staining with aqueous potassium permanganate or ethanolic phosphomolybdic acid solution. Flash column chromatography was performed using silica gel (300-400 mesh). Nuclear Magnetic Resonance (NMR) spectras were acquired on a Varian Mercury 400 operating at 400, 100 and 376 MHz for ^1H , ^{13}C and ^{19}F , respectively. Chemical shifts are reported in δ ppm referenced to an internal SiMe_4 standard for ^1H NMR, chloroform-d (δ 77.16) for ^{13}C NMR. Datas for ^1H NMR are recorded as follows: chemical shift (δ ppm), multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br s, broad), coupling constant (Hz) and integration. Datas for ^{13}C NMR and ^{19}F NMR are reported in terms of chemical shift (δ , ppm). High-resolution mass spectra (HRMS) were recorded on a Thermo Q-Exactive Spectrometer (ESI).

2. General Procedure for Synthesis of Barbiturate-Derived Alkenes 1

Method A: To a stirred solution of 1,3-dimethylbarbiturate (2 mmol, 1 equiv) in water (16 mL), the aldehydes was added (2 mmol, 1 equiv) rapidly and all at once. After stirring for about two hours, the produced solid was isolated by simple filtration. Dry the solid. The product **1** was identified by ^1H NMR analysis and could be used without further purification.¹

Method B: 1,3-dimethylbarbiturate (10 mmol), the aldehydes (30 mmol) and $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (5 mmol) were added sequentially to 20 mL of CH_2Cl_2 and the resulting mixture was stirred at room temperature for about 20 h. After the reaction was completed, the solution was evaporated in vacuo. The residue was purified through flash column chromatography to afford the corresponding product **1**.²

5-Benzylidene-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (1a).³ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.58 (s, 1H), 8.07-8.04 (m, 2H), 7.55-7.45 (m, 3H), 3.43 (s, 3H), 3.38 (s, 3H) ppm.

5-(4-Methoxybenzylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (1b).³ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.52 (s, 1H), 8.35-8.31 (m, 2H), 7.00-6.96 (m, 2H), 3.91 (s, 3H), 3.42 (s, 3H), 3.40 (s, 3H) ppm.

1,3-Dimethyl-5-(4-methylbenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (1c).⁴ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.55 (s, 1H), 8.08-8.05 (m, 2H), 7.30-7.28 (m, 2H), 3.42 (s, 3H), 3.38 (s, 3H), 2.44 (s, 3H) ppm.

5-(4-Fluorobenzylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (1d).⁵ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.53 (s, 1H), 8.22-8.17 (m, 2H), 7.19-7.13 (m, 2H), 3.43 (s, 3H), 3.39 (s, 3H) ppm.

5-(4-Chlorobenzylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (1e).⁶ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.51 (s, 1H), 8.05-8.02 (m, 2H), 7.46-7.43 (m, 2H), 3.43 (s, 3H), 3.38 (s, 3H) ppm.

5-(4-Bromobenzylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (1f).³ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.48 (s, 1H), 7.95-7.93 (m, 2H), 7.61-7.59 (m, 2H), 3.42 (s, 3H), 3.37 (s, 3H) ppm.

4-((1,3-Dimethyl-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl)benzotrile (1g).⁷ Synthesized

according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.53 (s, 1H), 7.95-7.93 (m, 2H), 7.74-7.72 (m, 2H), 3.44 (s, 3H), 3.36 (s, 3H) ppm.

1,3-Dimethyl-5-(4-(trifluoromethyl)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (Ih).⁸ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.57 (s, 1H), 7.80-7.98 (m, 2H), 7.72-7.70 (m, 2H), 3.44 (s, 3H), 3.37 (s, 3H) ppm.

1,3-Dimethyl-5-(4-nitrobenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (Ii).³ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.84-8.83 (m, 1H), 8.57 (s, 1H), 8.36-8.34 (m, 1H), 8.19-8.16 (m, 1H), 7.68-7.64 (m, 1H), 3.45 (s, 3H), 3.38 (s, 3H) ppm.

5-(3-Methoxybenzylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (Ij).³ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.55 (s, 1H), 7.79-7.78 (m, 1H), 7.58-7.56 (m, 1H), 7.40-7.36 (m, 1H), 7.10-7.08 (m, 1H), 3.87 (s, 3H), 3.43 (s, 3H), 3.38 (s, 3H) ppm.

5-(3-Fluorobenzylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (Ik).⁴ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.51 (s, 1H), 7.93-7.90 (m, 1H), 7.69-7.67 (m, 1H), 7.47-7.41 (m, 1H), 7.25-7.21 (m, 1H), 3.43 (s, 3H), 3.38 (s, 3H) ppm.

5-(3-Chlorobenzylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (Il).⁶ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.49 (s, 1H), 8.06-8.05 (m, 1H), 7.85-7.82 (m, 1H), 7.50-7.48 (m, 1H), 7.42-7.39 (m, 1H), 3.43 (s, 3H), 3.38 (s, 3H) ppm.

1,3-Dimethyl-5-(3-nitrobenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (Im).³ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.57 (s, 1H), 8.31-8.27 (m, 2H), 7.97-7.94 (m, 2H), 3.45 (s, 3H), 3.36 (s, 3H) ppm.

5-(2-Methoxybenzylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (In).⁹ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.89 (s, 1H), 8.04 (dd, $J = 7.8$ Hz, $J = 1.4$ Hz, 1H), 7.52-7.47 (m, 1H), 7.03-7.00 (m, 1H), 6.94 (d, $J = 8.4$ Hz, 1H), 3.90 (s, 3H), 3.42 (s, 3H), 3.35 (s, 3H) ppm.

1,3-Dimethyl-5-(2-methylbenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (Io).¹⁰ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.77 (s, 1H), 7.63 (d, $J = 7.6$ Hz, 1H), 7.39-7.35 (m, 1H), 7.26-7.23 (m, 2H), 3.43 (s, 3H), 3.32 (s, 3H), 2.36 (s, 3H) ppm.

5-(2-Bromobenzylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (Ip).⁴ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.65 (s, 1H), 7.69-7.64 (m, 2H), 7.40-7.36 (m, 1H), 7.34-7.30 (m, 1H), 3.44 (s, 3H), 3.32 (s, 3H) ppm.

1,3-Dimethyl-5-(2-(trifluoromethyl)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (Iq).⁴ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.81-8.79 (m, 1H), 7.75 (d, $J = 7.6$ Hz, 1H), 7.62-7.53 (m, 2H), 7.46-7.45 (m, 1H), 3.44 (s, 3H), 3.28 (s, 3H) ppm.

1,3-Dimethyl-5-(2-nitrobenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (Ir).⁶ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.89 (s, 1H), 8.30 (dd, $J = 8.0$ Hz, $J = 1.0$ Hz, 1H), 7.75-7.71 (m, 1H), 7.65-7.61 (m, 1H), 7.40-7.38 (m, 1H), 3.45 (s, 3H), 3.25 (s, 3H) ppm.

5-(2,4-Dimethoxybenzylidene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (Is).¹¹ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.98 (s, 1H), 8.56 (d, $J = 8.8$ Hz, 1H), 6.59-6.56 (m, 1H), 6.42 (d, $J = 2.4$ Hz, 1H), 3.91-3.90 (m, 6H), 3.41 (s, 3H), 3.37 (s, 3H) ppm.

1,3-Dimethyl-5-(naphthalen-1-ylmethylene)pyrimidine-2,4,6(1H,3H,5H)-trione (It).⁶ Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 9.24 (s, 1H), 8.00-7.95 (m, 2H), 7.93-7.86 (m, 2H), 7.59-7.53 (m, 3H), 3.48 (s, 3H), 3.32 (s, 3H) ppm.

1,3-Dimethyl-5-(naphthalen-2-ylmethylene)pyrimidine-2,4,6(1H,3H,5H)-trione (Iu).¹² Synthesized according to method A. ^1H NMR (400 MHz, CDCl_3) δ 8.74 (s, 1H), 8.60 (s, 1H), 8.16 (dd, $J = 8.8$ Hz,

$J = 1.6$ Hz, 1H), 7.96 (d, $J = 8.0$ Hz, 1H), 7.89-7.86 (m, 2H), 7.63-7.59 (m, 1H), 7.57-7.53 (m, 1H), 3.45 (s, 3H), 3.41 (s, 3H) ppm.

1,3-Dimethyl-5-(thiophen-3-ylmethylene)pyrimidine-2,4,6(1H,3H,5H)-trione (Iv).¹³ Synthesized according to method A. ¹H NMR (400 MHz, CDCl₃) δ 9.01-9.00 (m, 1H), 8.54 (s, 1H), 7.90 (dd, $J = 5.0$ Hz, $J = 1.0$ Hz, 1H), 7.40-7.38 (m, 1H), 3.42 (s, 3H), 3.41 (s, 3H) ppm.

5-(Benzo[d][1,3]dioxol-5-ylmethylene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (Iw).¹⁴ Synthesized according to method A. ¹H NMR (400 MHz, CDCl₃) δ 8.45 (s, 1H), 8.22 (d, $J = 1.6$ Hz, 1H), 7.62 (dd, $J = 8.4$ Hz, $J = 1.6$ Hz, 1H), 6.91 (d, $J = 8.4$ Hz, 1H), 6.10 (s, 2H), 3.41 (s, 3H), 3.39 (s, 3H) ppm.

5-(Cyclohexylmethylene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (Ix).⁴ Synthesized according to method A. ¹H NMR (400 MHz, CDCl₃) δ 7.78 (d, $J = 10.0$ Hz, 1H), 3.76-3.66 (m, 1H), 3.36 (s, 3H), 3.35 (s, 3H), 1.82-1.72 (m, 5H), 1.46-1.36 (m, 2H), 1.30-1.20 (m, 3H) ppm.

1,3-Dimethyl-5-(2-methylpropylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (Iy).¹⁵ Synthesized according to method B. ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, $J = 10.4$ Hz, 1H), 4.03-3.94 (m, 1H), 3.36 (s, 3H), 3.34 (s, 3H), 1.16 (s, 3H), 1.15 (s, 3H) ppm.

3. General Procedure for Synthesis of *N*-Alkoxy α -Haloamides **2**¹⁶

Method A: To a solution of *O*-substituted hydroxylamine hydrochloride (15 mmol, 1.0 equiv) in ethyl acetate/water (75/75 mL), Na₂CO₃ (30 mmol, 2.0 equiv) was added. The reaction mixture was then cooled to 0 °C in an ice water bath. Next, 2-halo acyl bromide (18 mmol, 1.2 equiv) was added dropwise to the reaction mixture. The reaction was stirred at 0 °C under air atmosphere. After 4 h, the mixture was allowed to warm to room temperature. The resulting mixture was diluted with ethyl acetate and washed with 3x water, followed by brine. The organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. When the solvent is concentrated to 3-5 mL, add 40-50 mL petroleum ether and place it in the refrigerator at -20 °C for 30 min. Filter to get white powdery *N*-alkoxy α -haloamides **2** and the products can be used without further purification.

Method B: To a solution of *O*-substituted hydroxylamine hydrochloride (12.5 mmol, 1.0 equiv) in dichloromethane (50 mL), triethylamine (1.75 mL, 12.5 mmol, 1.0 equiv) was added. The reaction mixture was then cooled to 0 °C in an ice water bath. Next, 2-halo acyl bromide (12.5 mmol, 1.0 equiv) was added dropwise to the reaction mixture. The reaction was stirred at 0 °C under air atmosphere. After 4 h, the mixture was allowed to warm to room temperature. The reaction was then quenched with water. The resulting mixture was diluted with CH₂Cl₂ and washed with 3x water, followed by brine. The organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude reaction mixture was purified by silica gel chromatography (PE/EtOAc) to give *N*-alkoxy α -haloamides **2**.

N-(benzyloxy)-2-bromoacetamide (**2a**).¹⁶ Synthesized according to method A. ¹H NMR (400 MHz, CDCl₃) δ 8.69 (s, 1H), 7.42-7.38 (m, 5H), 4.95 (s, 2H), 3.80 (s, 2H) ppm.

N-(benzyloxy)-2-chloroacetamide (**2b**).¹⁶ Synthesized according to method A. ¹H NMR (400 MHz, CDCl₃) δ 8.97 (s, 1H), 7.42-7.38 (m, 5H), 4.94 (s, 2H), 4.01 (s, 2H) ppm.

2-Bromo-*N*-methoxyacetamide (**2c**).¹⁶ Synthesized according to method B. ¹H NMR (400 MHz, CDCl₃) δ 9.83 (s, 1H), 3.83-3.81 (m, 5H) ppm.

2-Bromo-*N*-(naphthalen-2-ylmethoxy)acetamide (**2d**).¹⁶ Synthesized according to method A. ¹H NMR (400 MHz, CDCl₃) δ 8.75 (s, 1H), 7.90-7.85 (m, 4H), 7.55-7.51 (m, 3H), 5.10 (s, 2H), 3.77 (s, 2H) ppm.

N-benzyl-2-bromoacetamide (**2e**).¹⁶ Synthesized according to method A. ¹H NMR (400 MHz, CDCl₃) δ

7.39-7.29 (m, 5H), 6.75 (s, 1H), 4.49 (d, $J = 6.0$ Hz, 2H), 3.94 (s, 2H) ppm.

N-(benzyloxy)-2-bromopropanamide (**2f**).¹⁶ Synthesized according to method A. ¹H NMR (400 MHz, CDCl₃) δ 8.84 (s, 1H), 7.42-7.36 (m, 5H), 4.96-4.90 (m, 2H), 4.28-4.27 (m, 1H), 1.86-1.83 (m, 3H) ppm.

N-(benzyloxy)-2-bromobutanamide (**2g**).¹⁶ Synthesized according to method A. ¹H NMR (400 MHz, CDCl₃) δ 8.93-8.90 (m, 1H), 7.40-7.38 (m, 5H), 4.96-4.90 (m, 2H), 4.14-4.10 (m, 1H), 2.15-1.98 (m, 2H), 1.00 (t, $J = 7.0$ Hz, 3H) ppm.

N-(benzyloxy)-2-bromopentanamide (**2h**).¹⁶ Synthesized according to method A. ¹H NMR (400 MHz, CDCl₃) δ 8.81 (s, 1H), 7.40-7.38 (m, 5H), 4.96-4.90 (m, 2H), 4.17-4.14 (m, 1H), 2.07-1.91 (m, 2H), 1.49-1.40 (m, 2H), 0.93(t, $J = 7.4$ Hz, 3H) ppm.

N-(benzyloxy)-2-bromohexanamide (**2i**).¹⁶ Synthesized according to method A. ¹H NMR (400 MHz, CDCl₃) δ 8.95 (s, 1H), 7.40-7.38 (m, 5H), 4.96-4.90 (m, 2H), 4.16-4.12 (m, 1H), 1.98-1.86 (m, 2H), 1.41-1.32 (m, 4H), 0.92-0.88 (m, 3H) ppm.



N-(benzyloxy)-2-bromo-2-phenylacetamide (**2j**).¹⁷ Synthesized according to method A. ¹H NMR (400 MHz, CDCl₃) δ 9.05 (br s, 1H), 7.40-7.32 (m, 10H), 5.19 (s, 1H), 4.92 (s, 2H) ppm.



N-(benzyloxy)-2-bromo-2-methylpropanamide (**2k**).¹⁶ Synthesized according to method A. ¹H NMR (400 MHz, CDCl₃) δ 9.00 (s, 1H), 7.35-7.32 (m, 5H), 4.87-4.86 (m, 2H), 1.87-1.84 (m, 6H) ppm.



4. References



- (1) M. L. Deb and P. J. Bhuyan, *Tetrahedron Lett.*, 2005, **46**, 6453.
- (2) M. Szostak, B. Sautier, M. Spain, M. Behlendorf and D. J. Procter, *Angew. Chem. Int. Ed.*, 2013, **52**, 12559.
- (3) M. C. Rezendea and I. Almodovar, *Magn. Reson. Chem.*, 2012, **50**, 266.
- (4) H.-L. Liu, Y. Liu, C.-H. Yuan, G.-P. Wang, S.-F. Zhu, Y. Wu, B. Wang, Z.-H. Sun, Y.-M. Xiao, Q.-L. Zhou and H.-C. Guo, *Org. Lett.*, 2016, **18**, 1302.
- (5) M. K. Haldar, M. D. Scott, N Sule, D. K. Srivastavab and S. Mallik, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 2373.
- (6) K. M. Khan, M. Khan, M. Ali, M. Taha, A. Hameed, S. Ali, S. Perveen and M. I. Choudhary, *Med. Chem.*, 2011, **7**, 231.
- (7) K. Rehse and W-D Kapp, *Arch. Pharm.*, 1982, **315**, 346.
- (8) K. Tanaka, X. Chen, T. Kimura and F. Yoneda, *Chem. Pharm. Bull.*, 1988, **36**, 60.
- (9) H.-W. Zhao, N.-N. Feng, J.-M. Guo, J. Du, W.-Q. Ding, L.-R. Wang and X.-Q. Song, *J. Org. Chem.*, 2018, **83**, 9291.
- (10) X.-B. Yan, P. Shao, X. Song, C.-F. Zhang, C. Lu, S.-T. Liu and Y. -L. Li, *Org. Biomol. Chem.*, 2019, **17**, 2684.
- (11) M. B. Teimouri, P. Akbari-Moghaddam and M. Motaghinezhad, *Tetrahedron.*, 2013, **69**, 6804.
- (12) S.-I. Naya, M. Miyagawa and M. Nitta, *Tetrahedron.*, 2005, **61**, 4919.
- (13) K. A. Krasnov, V. G. Kartsev and A. S. Gorovoi, *Chem. Nat. Compd.*, 2000, **36**, 192.
- (14) D.-W. Shi, J.-W. Shi and S.-F. Rong, *Chin. J. Chem.*, 2010, **28**, 791.
- (15) X.-B. Yan, P. Shao, X. Song, C.-F. Zhang, C. Lu, S.-T. Liu and Y.-L. Li, *Org. Biomol. Chem.*, 2019, **17**, 2684.
- (16) J. Zhou, H. Zhang, X.-L. Chen, Y.-L. Qu, Q. Zhu, C.-G. Feng and Y.-J. Chen, *J. Org. Chem.*, 2019, **84**, 9179.
- (17) S.-J. Zhou, X. Cheng and J. Xuan, *Asian J. Org. Chem.*, 2019, **8**, 1376.



5. Copies of NMR Spectras of Barbiturate-Derived Alkenes 1




















































6. Copies of NMR Spectras of *N*-Alkoxy α -Haloamides 2























7. Copies of NMR spectras of adducts 3, 4 and 5










































































CDCl₃, 400 MHz




CDCl₃, 100 MHz



-57.14





3qa

CDCl₃, 376 MHz











CDCl₃, 400 MHz







CDCl₃, 100 MHz





















































CDCl₃, 400 MHz



CDCl₃, 100 MHz